Brusatol modulates diverse cancer hallmarks and signaling pathways as a potential cancer therapeutic

Announcing a new review article publication for Acta Materia Medica journal.   Cancer is a consequence of uncontrolled cell proliferation that is associated with cell-cycle disruption. It is a multifactorial disease that depends on the modulation of numerous oncogenic signaling pathways and targets and is a major cause of death worldwide.

Because of the development of resistance to current anticancer drugs, substantial effort has been focused on discovering more effective agents for tumor therapy. Natural products have powerful prospects as anticancer drugs. Brusatol, a component isolated from the plant Brucea javanica, has been demonstrated to efficiently combat a wide variety of tumors. Extensive studies have indicated that brusatol exhibits anticancer effects by arresting the cell cycle; promoting apoptosis; inducing autophagy; attenuating epithelial-mesenchymal transition; inhibiting migration, invasion and angiogenesis; and increasing chemosensitivity and radiosensitivity. These effects involve various oncogenic signaling pathways, including the MAPK, NF-κB, PI3K/AKT/mTOR, JAK/STAT and Keap1/Nrf2/ARE signaling pathways.

This review article describes the evidence suggesting that brusatol is a promising drug candidate for cancer therapeutics.

Article Reference: Song-Bin Guo, Wei-Juan Huang and Xiao-Peng Tian. Brusatol modulates diverse cancer hallmarks and signaling pathways as a potential cancer therapeutic. Acta Materia Medica. Vol. 1(3):278-301. DOI: 10.15212/AMM-2022-0014

Keywords: brusatol, cancer therapy, molecular target, traditional Chinese medicine (TCM)

Acta Materia Medica welcomes the submission of research articles, review articles, databases, mini reviews, commentaries, editorials, short communications, case report articles and study protocols.

Submission Process

Submissions to Acta Materia Medica are made using ScholarOne, the online submission and peer review system. Registration and access are available at

Queries about the journal can be sent to

Please visit to learn more about the journal.

Editorial Board:

There are no author submission or article processing fees.

Follow Acta Materia Medica on Twitter; Facebook (

eISSN 2737-7946